UHPLC-HRMS Lipidomics and Post-Stroke Cognition

Many stroke survivors go on to develop problems with memory, thinking, or concentration — a condition known as post-stroke cognitive impairment (PSCI). This can seriously affect their independence and quality of life down the road. The problem is that doctors currently do not have the proper tools to predict early on which patients are most at risk. One clue that researchers are exploring is fat (lipid) metabolism. There is evidence that when the body's fat processing goes out of balance, it may play a role in strokes caused by blocked blood flow (ischemic strokes), and possibly in the cognitive problems that follow.

A team of researchers decided to look closely at blood samples from patients who had just had an ischemic stroke, to see if early changes in blood fats could help flag who's more likely to develop PSCI. They also tested whether combining this fat-related information with standard clinical data (like a patient's age, symptoms, or health history) could make predictions more accurate. To do this, they used ultra-high-performance liquid chromatography–high-resolution mass spectrometry (UHPLC-HRMS), which can detect and measure a huge range of different fat molecules in a blood sample all at once. The findings from this work were published in the journal Frontiers in Neurology.¹

Why Do Current Methods for Detecting Post-Stroke Cognitive Impairment Fall Short, and What's Needed Instead?

Cognitive problems after a stroke, such as trouble with memory, focus, or thinking clearly, are a common and serious issue for stroke survivors. They can make it harder for people to enjoy life, recover well during rehabilitation, and get back to their normal social routines. On top of that, people who develop these problems face a higher risk of going on to develop dementia, and even a higher risk of dying earlier.^2,3

Currently, doctors mainly rely on memory and thinking tests, along with brain scans, to spot cognitive problems after a stroke early on. This includes short pen-and-paper style tests (like the Mini-Mental State Exam or the Montreal Cognitive Assessment) as well as imaging tools like cranial computed tomography (CT) and structural magnetic resonance imaging (MRI) scans to look at the brain's structure.^4-6However, the researchers who worked on the abovementioned study point out that these methods are not perfect. The memory and thinking tests can be thrown off by things that have nothing to do with actual cognitive decline, like how much schooling someone had, their language skills, their mood, or even quirks in how the person giving the test administers it. In addition, brain scans have their own downsides: they are expensive, take time, and are not always easy to access. CT scans specifically expose patients to radiation, and, while MRI avoids that, it takes longer to complete and is not a good fit for every patient.¹

“Therefore,” write the authors of the paper,¹ “simple, objective, and readily accessible blood-based biomarkers are urgently needed for the early identification of PSCI in clinical practice.”

Can Early Blood Lipid Changes, Alone or Combined with Clinical Data, Help Predict Which Stroke Patients Will Develop Cognitive Impairment?

The researchers followed 123 patients who had just had an ischemic stroke, taking a blood sample within the first 24 hours. Three months later, they tested each patient's thinking and memory skills over the phone using a standard cognitive screening tool. Based on the results, patients were split into two groups: those who developed thinking/memory problems (PSCI) and those whose cognition stayed normal (PSCN).¹

To find which blood fats might be linked to these cognitive problems, the team used several statistical methods, including comparing the two groups directly, adjusting for other health factors, looking at which biological pathways were involved, and using a technique that helps narrow down a large list of candidates to the most meaningful ones. They then built and tested three different prediction models: one based on standard clinical information, one based on the blood fat data, and one that combined both.¹

Out of the 123 patients, 62 went on to develop cognitive problems and 61 did not. The blood tests picked up over 1,500 distinct fat-related substances. At first glance, 87 of these looked different between the two groups, but after accounting for the fact that testing so many substances increases the chance of false positives, none of these differences held up as statistically solid on their own. However, once the researchers adjusted for other clinical factors, 65 of these fats still showed a nominal link to cognitive problems. Looking at the bigger picture, the affected fats mostly belonged to two related biological pathways involved in cell membrane building blocks and choline processing (choline is a nutrient tied to brain and nerve function). One fat molecule in particular, called LPC 22:6/0:0, stood out as an especially useful marker.¹

When the researchers tested how well each model could predict who would develop cognitive problems, the clinical-only model performed reasonably well, the blood-fat-only model performed more modestly, and the combined model (using both types of information together) performed the best. This combined model was not only fairly accurate, but also well-calibrated (meaning its risk estimates closely matched what actually happened), and it showed promise for being genuinely useful in real-world clinical decision-making.¹

“These findings,” write the authors of the paper,¹ “suggest early serum lipid metabolic alterations in patients who developed PSCI. LPC 22:6/0:0 may be associated with post-stroke cognitive outcomes, and a model integrating clinical and lipidomic features may support early PSCI risk stratification.”

References

1. Zhang, X.; Hao, X.; Chen, J. et al. Serum Lipidomic Alterations Associated with Post-Stroke Cognitive Impairment: An Exploratory Prospective Study. Front Neurol. 2026, 17, 1882198. DOI: 10.3389/fneur.2026.1882198
2. Wang, Y. J.; Li, Z. X.; Gu, H. Q. et al. China Stroke Statistics: an update on the 2019 report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations. Stroke Vasc Neurol. 2022, 7 (5), 415-450. DOI: 10.1136/svn-2021-001374
3. Gallucci, L.; Sperber, C.; Guggisberg, A. G. et al. Post-Stroke Cognitive Impairment Remains Highly Prevalent and Disabling Despite State-of-the-Art Stroke Treatment. Int J Stroke 2024, 19 (8), 888-897. DOI: 10.1177/17474930241238637
4. Salvadori, E.; Cova, I.; Mele, F. et al. Prediction of Post-Stroke Cognitive Impairment by Montreal Cognitive Assessment (MoCA) Performances in Acute Stroke: Comparison of Three Normative Datasets. Aging Clin Exp Res. 2022, 34 (8), 1855-1863. DOI: 10.1007/s40520-022-02133-9
5. Zietemann, V.; Georgakis, M. K.; Dondaine, T. et al. Early MoCA Predicts Long-Term Cognitive and Functional Outcome and Mortality After Stroke. Neurology 2018, 91 (20), e1838-e1850. DOI: 10.1212/WNL.0000000000006506
6. Zhang, C.; Wang, Y.; Li, S. et al. Infarct Location and Cognitive Change in Patients After Acute Ischemic Stroke: The ICONS Study. J Neurol Sci. 2022, 438, 120276. DOI: 10.1016/j.jns.2022.120276